6.9192
Cybin Inc 주식(CYBN)의 최신 뉴스
Weekly Roundup on the Cannabis Sector & Psychedelic Sector - marketexclusive.com
Cybin advances Phase 3 trial for depression treatment By Investing.com - Investing.com South Africa
Cybin Announces Additional Strategic Clinical Site Partnerships - GuruFocus
Cybin Expands Strategic Partnerships for Phase 3 MDD Treatment Trials - TipRanks
Cybin (CYBN) Expands Strategic Partnerships for Phase 3 MDD Program | CYBN Stock News - GuruFocus
Cybin advances Phase 3 trial for depression treatment - Investing.com
Cybin Says Second Phase 3 Study Embrace Expected To Begin Mid-2025 - marketscreener.com
CYBNCybin Inc Latest Stock News & Market Updates - Stock Titan
Cybin Announces Additional Strategic Clinical Site Partnerships to Support PARADIGM, a Multinational Phase 3 Program Evaluating CYB003 - The Joplin Globe
(CYBN) Trading Report - news.stocktradersdaily.com
Cybin (CYBN) Partners with Osmind for Psychedelic Therapy Launch - GuruFocus
Psychedelic drug developer Cybin partners with Osmind (CYBN:NYSE) - Seeking Alpha
Cybin Partners with Osmind to Accelerate Commercial Preparation for its Clinical-Stage Psychiatry Programs - 01net
Cybin Partners With Osmind to Support Psychiatry Program Pipeline - marketscreener.com
Cybin Partners with Osmind to Accelerate Commercial Preparation for its Clinical-Stage Psychiatry Programs | CYBN Stock News - GuruFocus
Cybin's Game-Changing Mental Health Partnership: 800+ Clinics to Deploy Novel Depression and Anxiety Treatments - Stock Titan
Where are the Opportunities in (CYBN) - news.stocktradersdaily.com
Filament Health secures investment to remedy concerning financial position - Mugglehead Magazine
4 Psychedelic Stocks to Buy Now - The Motley Fool
CYBN Stock Forecast: Projections From 2025 To 2040 - Exla Resources
Cybin to Participate in Cowen’s Psychedelics & Novel Mechanisms in Neuropsychiatry Virtual Summit on July 13th - Business Wire
Cybin wins new Buy from Guggenheim: potential to challenge J&J’s Spravato cited - MSN
(CYBN) Investment Analysis and Advice - news.stocktradersdaily.com
Guggenheim Initiates Coverage of Cybin (CYBN) with Buy Recommendation - Nasdaq
Cybin initiated with a Buy at Guggenheim - TipRanks
Cybin Inc. Reports Q3 2025 Financial Results and Strategic Progress - TipRanks
Psychedelic Science 2025 Announces Select Speakers for the Leading Conference on Psychedelic Research, Policy, and Thought Leadership - GlobeNewswire Inc.
Cybin Inc. (CYBN) Loses -25.81% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner - Nasdaq
Cybin Inc. (CYBN): Among the Best Psychedelic Stocks to Buy in 2025 - Insider Monkey
12 Best Psychedelic Stocks to Buy in 2025 - Insider Monkey
Wall Street Analysts Think Cybin Inc. (CYBN) Could Surge 988.67%: Read This Before Placing a Bet - MSN
Cybin (OTCMKTS:CLXPF) Shares Down 2.5%Here's What Happened - MarketBeat
How to Take Advantage of moves in (CYBN) - news.stocktradersdaily.com
Revolutionizing Mental Health Through Psychedelic Therapeutics | by Dr. Gleb Tsipursky | Feb, 2025 - DataDrivenInvestor
Cybin (NYSE:CYBN) Price Target Cut to $150.00 by Analysts at HC Wainwright - MarketBeat
Cybin (OTCMKTS:CYBN) Trading Up 1.2%Here's Why - MarketBeat
Canaccord cuts Cybin stock target to $73, maintains Buy rating - MSN
Cybin (NYSE:CYBN) Price Target Lowered to $73.00 at Canaccord Genuity Group - MarketBeat
Cybin stock price target cut to $150 at H.C. Wainwright - MSN
Cybin stock price target cut to $150 at H.C. Wainwright By Investing.com - Investing.com Australia
Canaccord cuts Cybin stock target to $73, maintains Buy rating By Investing.com - Investing.com Nigeria
(CYBN) Investment Analysis - Stock Traders Daily
자본화:
|
볼륨(24시간):